Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business UpdateGlobeNewsWire • 08/06/25
Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing and Treatment Recommendations Added to NCCN Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC)GlobeNewsWire • 08/06/25
Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of DirectorsGlobeNewsWire • 08/04/25
Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings GrowthZacks Investment Research • 07/30/25
Buy These 4 Stocks With Solid Net Profit Margin to Maximize ReturnsZacks Investment Research • 07/22/25
Catalyst Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025GlobeNewsWire • 07/22/25
Catalyst (CPRX) Loses 12.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 06/26/25
Catalyst Pharmaceuticals, Inc. (CPRX) Hits Fresh High: Is There Still Room to Run?Zacks Investment Research • 06/10/25
Catalyst (CPRX) Up 11.4% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 06/06/25
What Makes Catalyst Pharmaceutical (CPRX) a Strong Momentum Stock: Buy Now?Zacks Investment Research • 06/04/25
Does Catalyst (CPRX) Have the Potential to Rally 36.22% as Wall Street Analysts Expect?Zacks Investment Research • 06/02/25
Catalyst (CPRX) Is a Great Choice for 'Trend' Investors, Here's WhyZacks Investment Research • 06/02/25
Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical OfficerGlobeNewsWire • 06/02/25
Compared to Estimates, Catalyst (CPRX) Q1 Earnings: A Look at Key MetricsZacks Investment Research • 05/08/25